PExA (PEXA) Q4 2025 earnings summary

Executive summary

• Strategic shift from broad research use to focused clinical application, emphasizing lung cancer diagnostics and biomarker-driven solutions.

• 2025 marked by patent filings, new research collaborations, and increased international visibility, especially in lung cancer and immunology.

• Fully guaranteed rights issue of 9.9 MSEK strengthened financial position and enabled continued strategic investments.

Financial highlights

• Net sales for Q4 2025: 120,614 SEK (468,418 SEK in Q4 2024); full year 2025: 477,683 SEK (719,619 SEK in 2024).

• Result after financial items for Q4 2025: 891,616 SEK (-2,952,061 SEK in Q4 2024); full year: -6,247,135 SEK (-10,162,729 SEK in 2024).

• Earnings per share for Q4: 0.01 SEK (-0.06); full year: -0.08 SEK (-0.18).

• Cash and cash equivalents at year-end: 6,240,252 SEK (5,593,433 SEK in 2024).

• Total cash flow for 2025: 646,819 SEK (-4,006,513 SEK in 2024).

Outlook and guidance

• Board assesses available funds are insufficient for the next 12 months' operations and planned initiatives; discussions ongoing for additional capital.

• Continued focus on platform development, biomarker discovery, and clinical validation in 2026.